Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Recruiting · NCT06240143 · Registry updated 2024-11-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2024-11-14 | NCT06240143 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The Netherlands Cancer Institute | 113 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Amsterdam University Medical Center | Amsterdam | Netherlands | 35 |
| Antoni van Leeuwenhoek Hospital | Amsterdam | Netherlands | 3 |
| Erasmus University Medical Center | Rotterdam | Netherlands | 21 |
| Leiden University Medical Center | Leiden | Netherlands | 54 |
| University Medical Center Groningen | Groningen | Netherlands | 66 |
| University Medical Center Utrecht | Utrecht | Netherlands | 28 |